Evidence map›Paper›PMID 35955853›Full record

ReviewInternational journal of molecular sciences2022

Unifying Different Cancer Theories in a Unique Tumour Model: Chronic Inflammation and Deaminases as Meeting Points.

Pablo Hernández-Camarero, Elena López-Ruiz, Juan Antonio Marchal, Macarena Perán

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pablo Hernández-CamareroDepartment of Health Sciences, Campus de las Lagunillas SN, University of Jaén, E-23071 Jaén, Spain.
Elena López-RuizDepartment of Health Sciences, Campus de las Lagunillas SN, University of Jaén, E-23071 Jaén, Spain.
Juan Antonio MarchalExcellence Research Unit "Modeling Nature" (MNat), University of Granada, E-18016 Granada, Spain.ORCID 0000-0002-4996-8261
Macarena PeránDepartment of Health Sciences, Campus de las Lagunillas SN, University of Jaén, E-23071 Jaén, Spain.

Funding

Chair "Doctors Galera-Requena in cancer stem cell research" CMC-CTS963Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía SOMM17/6109/UGRConsejería de Salud y Familias de la Junta de Andalucía PEMP-0205-2020Ministry of Economy and Competitiveness PIE16/00045Ministry of Science, Innovation and Universities RTI2018-101309-B-C22University of Jaen, Acción I apoyo a la investigación BIO-349
6 · The paper itself

Abstract

The increase in cancer incidences shows that there is a need to better understand tumour heterogeneity to achieve efficient treatments. Interestingly, there are several common features among almost all types of cancers, with chronic inflammation induction and deaminase dysfunctions singled out. Deaminases are a family of enzymes with nucleotide-editing capacity, which are classified into two main groups: DNA-based and RNA-based. Remarkably, a close relationship between inflammation and the dysregulation of these molecules has been widely documented, which may explain the characteristic intratumor heterogeneity, both at DNA and transcriptional levels. Indeed, heterogeneity in cancer makes it difficult to establish a unique tumour progression model. Currently, there are three main cancer models-stochastic, hierarchic, and dynamic-although there is no consensus on which one better resembles cancer biology because they are usually overly simplified. Here, to accurately explain tumour progression, we propose interactions among chronic inflammation, deaminases dysregulation, intratumor genetic heterogeneity, cancer phenotypic plasticity, and even the previously proposed appearance of cancer stem-like cell populations in the edges of advanced solid tumour masses (instead of being the cells of origin of primary malignancies). The new tumour development model proposed in this study does not contradict previously accepted models and it may open up a window to interesting therapeutic approaches.

Indexed as

NeoplasmsCytidine DeaminaseDNAHumansInflammationRNARNA EditingCytidine DeaminaseDNARNAADARAIDAPOBECcancer phenotype plasticitycancer stem cellsdeaminases dysregulationtumour development model

Identifiers

PMID35955853
PMCPMC9368936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.